Clinical Pharmacokinetics of Amikacin in Pediatric Patients: A Comprehensive Review of Population Pharmacokinetic Analyses
Amikacin plays a key role in the treatment of severe hospital-acquired infections with Gram-negative bacteria. Therapeutic use of amikacin is challenged by high inter-individual variability (IIV) combined with a narrow therapeutic spectrum. Pediatric patients represent a particularly fragile population where adequate dosing is crucial yet challenging to achieve due significant IIV associated with developmental processes and other factors. The current review provides an overview of parametric population pharmacokinetic analyses of amikacin in pediatric patients and associated patient-specific determinants of IIV. We searched PubMed for parametric population pharmacokinetic analyses of amikacin in pediatric patients. Information on patient population, study design, pharmacokinetic model characteristics, and identified patient-specific predictors of IIV was collected. Comparative analyses across studies were conducted to characterize quantitative differences reported for different studies and patient populations. Eight eligible publications were identified, of which six analyses involved neonates up to 3 months of age and two studies investigated older pediatric patients (age 2–17 years). Most commonly included covariates were current body weight for both clearance and volume of distribution, followed by age-related covariates on clearance in neonatal studies (four of six models). Quantitative comparisons of different models reported generally showed similar developmental effects in neonatal populations. The present review provides a comprehensive overview of parametric population pharmacokinetic studies for amikacin. Future studies could address the knowledge gap of patients between 3 months and 2 years of age. Furthermore, systematic studies of additional potential predictors for IIV (e.g., sepsis, inflammatory markers, renal function biomarkers) could be of relevance to address the significant IIV remaining after inclusion of the most commonly identified covariates.
Compliance with Ethical Standards
No sources of funding were used to assist with the preparation of this review.
Conflict of interest
Sílvia M. Illamola, Catherine M. Sherwin, and J. G. Coen van Hasselt have no conflicts of interest that are relevant to the content of this review.
- 1.Boehr DD, Draker KA, Wright GD. Aminoglycoside and aminocyclitols. In: Finch RG, Greenwood D, Norrby SR, Whitley RJ, editors. Antibiotic and chemotherapy: anti-infective agents and their use in therapy. New York: Churchill Livingstone; 2003. pp. 155–84.Google Scholar
- 2.Spitzer AR, Ellsbury DL, Handler D, Clark RH. The Pediatrix BabySteps® Data Warehouse and the Pediatrix QualitySteps Improvement Project System–tools for “meaningful use” in continuous quality improvement. Clin Perinatol. 2010;37(1):49–70. https://doi.org/10.1016/j.clp.2010.01.016.CrossRefPubMedGoogle Scholar
- 3.BMS. Amikacin. Summary of product characteristics. Princeton, NJ: BMS; 2014.Google Scholar
- 8.Zaske D. Applied pharmacokinetics. Principles of therapeutic drug monitoring. 3rd ed. Vancouver: Applied Therapeutics; 1992.Google Scholar
- 17.Smits A, De Cock RFW, Allegaert K, Vanhaesebrouck S, Danhof M, Knibbe CAJ. Prospective evaluation of a model-based dosing regimen for amikacin in preterm and term neonates in clinical practice. Antimicrob Agents Chemother. 2015;59(10):6344–51. https://doi.org/10.1128/Aac.01157-15.CrossRefPubMedPubMedCentralGoogle Scholar